0 votes
7 views
ago in General Health by (560 points)
Is TALVEY immunotherapy?

1 Answer

0 votes
ago by (1.1k points)
Yes, TALVEY is immunotherapy, most specifically, TALVEY is a bispecific antibody (and a type of T-cell engager).

TALVEY works by simultaneously attaching to:

GPRC5D proteins on the surface of multiple myeloma cells.

CD3 proteins on the surface of T cells (part of your immune system)

By bringing the T cells directly into contact with the cancer cells, TALVEY activates your immune system to recognize and destroy the multiple myeloma cells.

TALVEY is approved for adults with heavily pretreated (at least 4 prior lines) relapsed or refractory multiple myeloma.

The drug TALVEY is a first-in-class GPRC5D-targeting bispecific T-cell engager developed by Janssen Biotech, Inc.

TALVEY is hazardous and carries significant medical and occupational hazards, which include a boxed warning from the FDA for severe as well as life threatening, or even fatal reactions, although it's generally safe for most people when used correctly and at proper dosages.

The potential side effects of taking TALVEY are mouth and taste changes, blood and immune issues, skin and nail changes, as well as general symptoms like fever (pyrexia), fatigue/tiredness, muscle or joint pain, diarrhea, nausea, and elevated liver enzymes.

Blood and immune issues that can occur with TALVEY include low white blood cell counts (neutropenia), low platelet counts (thrombocytopenia), and an increased risk of serious or life-threatening infections.

Mouth and Taste Changes that can occur with TALVEY include dysgeusia (changes in taste or metallic/cardboard taste), dry mouth, difficulty swallowing (dysphagia), mouth sores, and weight loss.

Serious and Boxed Warnings of TALVEY include.

Cytokine Release Syndrome (CRS), which is an inflammatory response causing high fever (100.4°F / 38°C or higher), chills, fast heartbeat, low blood pressure, or breathing difficulty.

It is common during step-up dosing, and patients are typically hospitalized for 48 hours after step-up doses of TALVEY.

Neurologic Toxicity (including ICANS): TALVEY can cause confusion, headaches, tremors, dizziness, sleepiness, difficulty speaking or thinking, seizures, or muscle weakness.

You should avoid driving or operating machinery during step-up dosing of TALVEY and if you experience dizziness or confusion.

The possible skin side effects of TALVEY are rashes and skin reactions, dry skin (Xerosis), Palmoplantar Peeling/ Skin Scaling, Nail Changes and even infection site reactions.

Rashes and Skin Reaction side effects of TALVEY include general rashes, maculo-papular rashes (small, flat red spots with raised bumps), and skin redness (erythema) which occur in a majority of people who are on TALVEY.

Dry Skin (Xerosis): Severe or generalized dry skin is frequent and can affect mucous membranes like the mouth and eyes.

Palmoplantar Peeling / Skin Scaling: Peeling or scaling of the skin, particularly on the palms of the hands and soles of the feet, can develop during treatment with TALVEY.

Nail disorders are also very common when being treated with TALVEY (impacting up to half of patients), including nail fragility, discoloration, ridging, or nails separating and lifting from the nail bed.

Injection Site Reactions of TALVEY include mild redness, swelling, pain, or irritation can happen where the subcutaneous injection is given.

While most skin reactions from TALVEY are mild to moderate and manageable with moisturizers, topical steroids, or dose adjustments, serious skin reactions can occasionally occur.

You should seek medical attention right away if you notice any of the following when being treated with TALVEY.

Blistering, severe peeling, or open sores on the skin.
Rashes accompanied by a fever or flu-like symptoms.

The drug TALVEY is a bispecific antibody that is also known as (talquetamab-tgvs) and is a first in class, T-cell-redirecting bispecific antibody that is also approved by the FDA for the treatment of adults that have heavily pretreated, relapsed or refractory multiple myeloma (a type of blood cancer).

The way that TALVEY works is unlike, traditional monoclonal antibodies, which only target one site, a bispecific antibody like TALVEY, has two distinct "arms" that also bind to tow different proteins simultaneously.

And one arm binds to GPRC5D (which is a protein found in high numbers on the surface of multiple myeloma cells).

And the other arm binds to CD3 (a protein located on the surface of your immune system's T cells).

TALVEY activates your immune system to attack and destroy the cancer cells, by bridging the T cell and myeloma cell together.

Talvey (talquetamab-tgvs) is an immunotherapy, not traditional chemotherapy.

Specifically, Talvey is a bispecific T-cell engager (BiTE) and a type of monoclonal antibody.

It acts like a bridge by attaching to two different proteins at the same time—GPRC5D on multiple myeloma cancer cells and CD3 on your body's immune T-cells.

By bringing them together, Talvey activates your T-cells to find, target, and destroy the cancer cells.

How it differs from chemotherapy: Traditional chemotherapy generally attacks and destroys any fast-growing cells in the body (both cancerous and healthy).

Talvey instead directs your own immune system to specifically recognize and fight the myeloma cells.

2.5k questions

2.5k answers

22 comments

141 users

VekDrive.com Cloud Storage and File Sharing.

Get 5 GB Free Cloud Storage when you signup for a free account.

Or get 50 GB of Cloud Storage for $3.00 per month.

VekDrive Cloud Storage

...